Jefferies Healthcare Conference, Day 2: Myriad; Danaher; Cepheid; Exact Sciences

Myriad and Cepheid discussed their pipelines, while Exact Sciences provided some details of its upcoming trial on its colon cancer test, and Danaher touted its success with past acquisitions as it nears closing of its Beckman Coulter buy.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.